BMYMP News and Press, Bristol-Myers Squibb $2Pr From 08/24/23

2023-08-24 02:20:26 ET Summary Bristol-Myers has a strong history of investment outperformance during equity bear markets and recessions. The company is uniquely undervalued, with a low 8x P/E and nearly 4% cash dividend yield. After a weak first half of 2023, shares may rebou...

2023-08-21 13:57:06 ET Summary On August 1, Merck released its financial report for the second quarter of 2023, which showed excellent results. Merck's revenue for the second quarter of 2023 was $15.04 billion, up 3.8% from the previous quarter and up 3.1% from the second quarter ...

2023-08-18 13:09:45 ET Summary On August 7, Viatris released its financial results for the 2nd quarter of 2023, which, after a long time, finally managed to beat analysts' expectations. Viatris' revenue for the second quarter of 2023 was $3.92 billion, up 5.1% from the previous qu...

2023-08-14 17:28:47 ET Summary Replimune Group, Inc. results from the registration-directed phase 2 CERPASS trial, using RP1 + Libtayo for the treatment of patients with cutaneous squamous cell carcinoma, are expected Q4 of 2023. The cutaneous squamous cell carcinoma treatment mar...

2023-08-14 05:45:30 ET Summary Coya Therapeutics is developing Treg-enhancing therapeutics to target diseases driven by inflammation, including in the central nervous system, including ALS. Coya Therapeutics' ALS drug could be approved based on pivotal phase 2 results and could po...

2023-08-13 07:00:00 ET Summary BeiGene and Bristol-Myers Squibb have completed the breakup of their partnership, with BeiGene regaining shares worth $340 million. Gracell Biotechnologies raised $100 million in a private placement to support the development of its CAR-T therapies. ...

2023-08-02 04:05:54 ET Summary High-beta stocks have outperformed defensive stocks in the stock market recently, raising questions about the effectiveness of low-volatility and dividend growth investing. ROBECO's research shows that low-volatility investing can significantly impro...

2023-07-29 08:03:02 ET Summary Bristol-Myers Squibb's revenue for the second quarter of 2023 was $11.23 billion, down 0.97% from the previous quarter and 5.6% from the second quarter of 2022. Sales of Opdualag, an FDA-approved drug for treating patients with unresectable or metast...

2023-07-28 10:45:41 ET Bristol-Myers Squibb Company PFD CONV 2 ( OTCPK:BMYMP ) had declared $0.50/share quarterly dividend. Payable Sept. 1; for shareholders of record Aug. 1; ex-div July 31. See BMYMP Dividend Scorecard, Yield Chart, & Dividend Growth. For furth...

2023-07-27 12:37:08 ET Bristol-Myers Squibb Company (BMY) Q2 2023 Earnings Call Transcript July 27, 2023 08:00 AM ET Company Participants Timothy Power - VP & Head, IR Giovanni Caforio - Chairman & CEO David Elkins - EVP & CFO Christopher Boerner ...